Robert Gemmill to Antineoplastic Agents
This is a "connection" page, showing publications Robert Gemmill has written about Antineoplastic Agents.
Connection Strength
0.553
-
MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. J Thorac Oncol. 2009 Apr; 4(4):472-8.
Score: 0.188
-
Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer. 2005 Jun 20; 92(12):2266-77.
Score: 0.144
-
Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021 08; 162(2):463-473.
Score: 0.102
-
Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol. 2009 Dec; 4(12):1455-65.
Score: 0.049
-
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006 Jan 15; 66(2):944-50.
Score: 0.038
-
ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One. 2016; 11(1):e0147344.
Score: 0.019
-
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012 Dec; 30(6):2303-17.
Score: 0.014